BIP

PF3D7_0917900 (BIP/PfGRP78) is an ER-resident HSP70-class molecular chaperone of Plasmodium falciparum, encoded by a gene expressed across asexual and sexual erythrocytic stages and homologous to mammalian GRP78 (PMID:3045815). Its ER residence is established directly by immuno-gold electron microscopy and by immunofluorescence, where it serves as a validated parasite ER marker distinct from the cis-Golgi, consistent with its non-canonical C-terminal SDEL retention signal (PMID:1779989, PMID:8223485). Unlike mammalian GRP78, BIP synthesis is not induced by heat shock, glucose deprivation, or classical ER-stress agents, defining a distinct stress-response profile (PMID:1779989). Functionally, BIP operates within the parasite ER quality-control machinery: it physically interacts with the ER co-chaperone PfGRP170 by reciprocal co-immunoprecipitation, and loss of PfGRP170 activates the eIF2α kinase PK4, placing BIP within the parasite unfolded protein response (PMID:31087747). BIP transcription is upregulated under artemisinin and stress conditions through direct binding of the histone acetyltransferase PfGCN5 at its locus, linking it to the artemisinin resistance response (PMID:33441725). Beyond the canonical ER pool, BIP partially localizes to the brefeldin A-sensitive Plasmodium export compartment and was identified as its 68-kDa component by mass spectrometry, implicating it in early steps of protein export to the host erythrocyte (PMID:12850257, PMID:32529065). The ATP-binding domain of BIP has been resolved crystallographically with ADP and with nucleoside-analogue fragment ligands, revealing parasite-specific active-site features exploitable for selective inhibition, and recombinant BIP is susceptible to chaperone inhibitors lethal to drug-sensitive and drug-resistant parasites, establishing it as a validated drug target (PMID:29985421, PMID:36275624).

1. 1988 Medium

   Establishing that P. falciparum encodes a GRP78-like chaperone answered whether the parasite possesses a dedicated ER HSP70 homolog, and its erythrocytic-stage expression defined when it is present.

   Evidence Genomic cloning, RNA blot, and immunoprecipitation of a 72-kDa protein with sequence homology analysis in P. falciparum

   PMID:3045815

   Open questions at the time

   • Subcellular localization inferred only from partial ER-retention signal, not directly shown
   • No chaperone activity demonstrated
   • No binding partners identified
2. 1991 Medium

   Direct localization resolved where BIP resides and whether it behaves like mammalian GRP78, showing it is an ER protein with a distinct, non-inducible stress-response profile.

   Evidence Immuno-gold EM, metabolic labeling, and induction assays (heat, glucose deprivation, A23187, tunicamycin, 2-deoxyglucose) in P. falciparum

   PMID:1779989

   Open questions at the time

   • SDEL retention mechanism proposed but not functionally tested
   • No molecular partners defined
   • Chaperone/folding function not assayed
3. 1993 Medium

   Using BIP as a reference marker confirmed its ER identity relative to the Golgi, resolving compartmental assignment within the parasite secretory pathway.

   Evidence Indirect immunofluorescence with brefeldin A perturbation and subcellular fractionation, comparing PfERD2 redistribution to the BIP ER pattern in P. falciparum

   PMID:8223485

   Open questions at the time

   • BIP used only as a marker; no new mechanistic role for BIP itself
   • No interaction data
4. 1993 Low

   Stage profiling asked whether BIP expression varies across the life cycle, revealing strong induction in liver stages and absence in sporozoites.

   Evidence Western blot and immunofluorescence of cultured exoerythrocytic stages in P. berghei (HepG2-A16) and P. falciparum (human hepatocytes in SCID mice)

   PMID:8475027

   Open questions at the time

   • Single study, expression only, no functional follow-up specific to BIP
   • Mechanism of stage-specific induction unknown
5. 2003 Low

   Co-localization with COPII coat proteins and export-compartment markers addressed whether BIP participates in parasite protein export, linking the ER to an early export domain.

   Evidence Co-localization immunofluorescence with Sar1p, Sec31p and PEC proteins under brefeldin A treatment in P. falciparum

   PMID:12850257

   Open questions at the time

   • Only partial co-localization, no functional assay on BIP
   • Export role remains inferential
6. 2018 High

   The ADP-bound crystal structure answered whether BIP has exploitable parasite-specific structural features, establishing it as a validated selective drug target.

   Evidence X-ray crystallography of the ATP-binding domain with ADP, recombinant inhibitor-binding characterization, and in vitro growth inhibition of drug-sensitive and drug-resistant P. falciparum

   PMID:29985421

   Open questions at the time

   • Only the ATP-binding domain resolved; substrate-binding domain not structurally defined
   • Inhibitor selectivity over human GRP78 in cells not fully quantified
7. 2019 Medium

   Identifying the PfGRP170 interaction and PK4 activation upon PfGRP170 loss placed BIP within a defined ER co-chaperone module and the parasite unfolded protein response.

   Evidence Reciprocal co-immunoprecipitation, TetR-DOZI conditional mutagenesis of PfGRP170, and immunofluorescence in P. falciparum

   PMID:31087747

   Open questions at the time

   • Direct chaperone cycle between BIP and PfGRP170 not reconstituted
   • Whether BIP loss itself triggers PK4 not tested
   • Client proteins of the complex unidentified
8. 2020 Medium

   Mass-spectrometric identification of the 68-kDa PEC component as BIP resolved the molecular identity of an export-compartment marker, reinforcing a role in host-cell protein export.

   Evidence Affinity purification with anti-PEC monoclonal antibody, peptide mapping mass spectrometry, and immunofluorescence in P. falciparum

   PMID:32529065

   Open questions at the time

   • Functional contribution of BIP to export not directly demonstrated
   • Client cargo not defined
9. 2021 Medium

   ChIP-seq mapping of PfGCN5 to the BIP locus answered how BIP expression is controlled under artemisinin stress, linking it to epigenetic regulation and the drug-resistance response.

   Evidence ChIP-seq of PfGCN5 binding and qRT-PCR expression analysis in artemisinin-exposed P. falciparum

   PMID:33441725

   Open questions at the time

   • Causal requirement of PfGCN5 for BIP induction not tested by perturbation
   • Downstream consequence of BIP upregulation for resistance unresolved
10. 2022 High

    Fragment-based crystallographic screening extended the drug-target case by mapping druggable sites on the ATP-binding domain distinct from human GRP78.

    Evidence X-ray crystallography ligand-soaking screen of 233 compounds identifying eight nucleoside-analogue hits, validated by protein thermal shift assay, on P. falciparum BIP

    PMID:36275624

    Open questions at the time

    • Hits not advanced to cellular potency or selectivity data
    • No lead optimization or in vivo validation

• The physiological client proteins of BIP and its direct mechanistic contribution to protein export to the host erythrocyte remain undefined.
• No BIP substrate/client repertoire identified
• Export role established only by localization, not by loss-of-function
• No conditional-knockdown phenotype for BIP itself reported